JPMorgan Downgrades Merrimack Pharmaceuticals (MACK) to Neutral

October 7, 2016 7:34 AM EDT
Get Alerts MACK Hot Sheet
Price: $3.00 --0%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 11 | New: 9
Trade MACK Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

JPMorgan downgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Overweight to Neutral with a price target of $7.00 (from $8.00).

For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.

Shares of Merrimack Pharmaceuticals closed at $5.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst PT Change, Downgrades

Related Entities

JPMorgan

Add Your Comment